Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. on January 30, 2009. The filing reports on material events occurring on that date, specifically the entry into a Forbearance Agreement regarding defaulted debt and a mutual release agreement with a former executive. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Key Financial Metrics and Debt Status
- Outstanding Debt: $2,170,500 aggregate principal amount of 6% convertible debentures remains outstanding.
- Defaulted Amounts Settled: $2,010,204 in accrued interest, penalties, late fees, and liquidated damages.
- Settlement Method: Issuance of 5,337,474 shares of common stock to debenture holders.
- Revised Interest Rate: Increased from 6% to 11%.
- Revised Maturity Date: Extended to December 31, 2010.
- Liquidity/Cash Flow: The filing does not provide specific cash flow or liquidity figures; however, the company settled accrued obligations via equity issuance rather than cash.
Material Changes Versus Prior Period
On November 14, 2008, the company failed to pay amounts due on the maturity date of the debentures, constituting an Event of Default. The current filing represents a material change in the terms of this debt:
- Transition from a state of default to a forbearance arrangement.
- Significant increase in the cost of capital (interest rate hike from 6% to 11%).
- Dilution of existing shareholders through the issuance of over 5.3 million shares to settle accrued liabilities.
- Extension of the debt maturity by approximately 21 months.
Guidance, Outlook, and Management Commentary
The filing does not contain forward-looking financial guidance or revenue outlooks. Key management actions and contingencies include:
- Board Composition: Certain debenture holders now hold rights to appoint two persons to the Company's Board of Directors.
- Compensation Controls: The agreement imposes conditions regarding the determination of compensation for officers and directors.
- Executive Departure: A mutual release agreement was executed with Dr. Gianluigi Longinotti-Buitoni, the former Executive Chairman, releasing both parties from claims and specific warrant/put option rights.
- Interest Payment Form: Future interest payments may be made in the form of Company common stock.
Important Facts for Investor Verification
- Verify the exact dilution impact of the 5,337,474 newly issued shares on existing shareholders.
- Confirm the specific terms regarding the appointment of the two new board members by debenture holders.
- Review the attached Forbearance Agreement (Exhibit 10.1) for detailed covenants and conditions on officer compensation.
- Assess the company's ability to service the increased 11% interest rate and the remaining $2.17 million principal by the new 2010 maturity date.
- Clarify the status of the Warrant and Put Option Agreement released in the settlement with the former Executive Chairman.